Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 830 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 830 shares of the firm’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $40.35, for a total transaction of $33,490.50. Following the completion of the sale, the insider owned 33,530 shares of the company’s stock, valued at $1,352,935.50. This trade represents a 2.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Castle Biosciences Trading Down 0.3%

Shares of Castle Biosciences stock opened at $39.27 on Tuesday. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -87.27 and a beta of 1.14. Castle Biosciences, Inc. has a 52-week low of $14.59 and a 52-week high of $42.17. The company’s 50-day simple moving average is $34.91 and its 200-day simple moving average is $25.64. The company has a quick ratio of 6.31, a current ratio of 6.47 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.32. Castle Biosciences had a positive return on equity of 1.73% and a negative net margin of 3.56%.The company had revenue of $80.55 million for the quarter, compared to analyst estimates of $71.06 million. As a group, equities research analysts anticipate that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Institutional Investors Weigh In On Castle Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Franklin Resources Inc. grew its holdings in Castle Biosciences by 0.5% during the 3rd quarter. Franklin Resources Inc. now owns 99,787 shares of the company’s stock valued at $2,272,000 after buying an additional 540 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Castle Biosciences by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock valued at $309,000 after acquiring an additional 655 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Castle Biosciences by 1.0% during the second quarter. Envestnet Asset Management Inc. now owns 70,478 shares of the company’s stock valued at $1,439,000 after acquiring an additional 707 shares during the last quarter. Inspire Investing LLC increased its position in Castle Biosciences by 4.0% during the 3rd quarter. Inspire Investing LLC now owns 19,887 shares of the company’s stock worth $453,000 after purchasing an additional 770 shares in the last quarter. Finally, CWM LLC increased its position in Castle Biosciences by 80.6% during the 3rd quarter. CWM LLC now owns 1,911 shares of the company’s stock worth $44,000 after purchasing an additional 853 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on CSTL. Robert W. Baird raised their price objective on shares of Castle Biosciences from $39.00 to $41.00 and gave the company an “outperform” rating in a research note on Tuesday, November 4th. BTIG Research lifted their price target on shares of Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Canaccord Genuity Group boosted their price target on Castle Biosciences from $37.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. Zacks Research raised Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Castle Biosciences in a report on Monday, December 22nd. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $41.00.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.